Computational Modeling of PancreaSolve-HNX: A Theoretical Framework for Multi-Modal Nanotherapy Dynamics in Pancreatic Ductal Adenocarcinoma Treatment

Pancreatic ductal adenocarcinoma (PDAC) persists as one of the deadliest solid malignan-cies, characterized by a 5-year relative survival rate of only 13% [1], primarily due to its denselyfibrotic and immunosuppressive tumor microenvironment (TME) that confers profound resis-tance to conventional chemotherapeutics [2]. The desmoplastic stroma, accounting for 80–90%of the tumor mass, erects a substantial physical and immunological barrier, severely limitingdrug penetration and efficacy [2]. In this study, we propose PancreaSolve-HNX, a ratio-nally engineered multi-modal hybrid organic–inorganic nanoparticle system featuring a goldcore integrated with sonosensitizers, a porous silica interlayer for structural stability, and aZr4+-based metal-organic framework (MOF) shell that facilitates ultra-high loading capacitiesexceeding 70% w/w for gemcitabine monophosphate (GMP) [3]. The nanoparticle surface ismeticulously functionalized with hyaluronidase-PEG conjugates to enable targeted degradationof hyaluronan-rich extracellular matrix [6], iRGD peptides to promote deep tumor penetration[11], and bispecific anti-CD47/PD-L1 nanobodies to disrupt immune checkpoint signaling andenhance antitumor immunity [10].To evaluate the therapeutic potential of this design, we develop a multi-scale system ofordinary differential equations (ODEs) that extends validated frameworks for PDAC TME in-teractions [7]. The model is calibrated using Bayesian inference via Hamiltonian Monte Carlosampling in PyMC, incorporating rigorous uncertainty quantification [8]. Global sensitivityanalysis employing Sobol indices elucidates the dominant parameters influencing efficacy. Nu-merical simulations predict that a single intravenous administration of PancreaSolve-HNX, com-bined with three sequential focused ultrasound sessions, achieves greater than 95% ablation ofviable tumor cells by day 7 through synergistic chemo-sonodynamic-photothermal mechanismsand induction of immunogenic cell death (ICD) [9]. This is followed by near-complete stromaldepletion by day 10, robust systemic antitumor immune activation by day 14, and sustainedtumor regression extending to 28 days. These outcomes, although contingent upon empiri-cal validation, demonstrate strong concordance with preclinical data for constituent modalities[4, 3] and highlight the transformative potential of integrated synergies in surmounting PDACtherapeutic barriers [5].Keywords: pancreatic ductal adenocarcinoma · hybrid nanoparticles · tumor microenviron-ment remodeling · mathematical oncology · sonodynamic therapy · Bayesian inference · immuno-genic cell death